Herantis Pharma presents positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease

Herantis Pharma announces positive topline data for HER-096 in Phase 1b trial for people living with Parkinson’s disease Trial meets all primary and secondary endpoints establishing a strong foundation to Phase 2 The clinical trial demonstrated that both repeated 200 mg and 300 mg doses of HER-096 are generally safe and well tolerated in Parkinson’s disease (PD) patients.Results from the clinical trial demonstrated a pharmacokinetic profile consistent with predictions from the single-dose studies in healt ...